CRH Medical logo CRH Medical (NYSEAMERICAN:CRHM) announced its earnings results on Wednesday, March 13th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02, Morningstar.com reports. The business had revenue of $32.02 million during the quarter, compared to analysts’ expectations of $31.40 million.
CRHM opened at $2.70 on Friday. CRH Medical has a twelve month low of $2.40 and a twelve month high of $4.50.
Several research firms have recently commented on CRHM. TD Securities reiterated a “buy” rating on shares of CRH Medical in a research report on Tuesday, January 8th. Zacks Investment Research downgraded shares of CRH Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, December 4th. Finally, Clarus Securities reaffirmed a “buy” rating on shares of CRH Medical in a research note on Wednesday, March 20th.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC grew its holdings in CRH Medical by 6.1% during the 4th quarter. Nantahala Capital Management LLC now owns 6,534,155 shares of the company’s stock worth $20,028,000 after acquiring an additional 378,329 shares in the last quarter. Beutel Goodman & Co Ltd. raised its position in shares of CRH Medical by 3.5% during the 4th quarter. Beutel Goodman & Co Ltd. now owns 5,127,100 shares of the company’s stock worth $1,570,000 after buying an additional 171,970 shares in the last quarter. Morgan Stanley raised its position in shares of CRH Medical by 116.7% during the 3rd quarter. Morgan Stanley now owns 3,653,460 shares of the company’s stock worth $14,432,000 after buying an additional 1,967,537 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of CRH Medical by 21.7% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,201,799 shares of the company’s stock worth $6,739,000 after buying an additional 392,900 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of CRH Medical by 38.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,486,400 shares of the company’s stock worth $5,871,000 after buying an additional 409,100 shares in the last quarter.
About CRH Medical
CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O’Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. Earnings History for CRH Medical (NYSEAMERICAN:CRHM) Receive News & Ratings for CRH Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRH Medical and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at CRH Medical (CRHM) Posts Quarterly Earnings Results, Hits Estimates